Supplementary Material for: Response of Retinoic Acid in Patients with Radioactive Iodine-Refractory Thyroid Cancer: A Meta-Analysis
Pak K.
Shin S.
Kim S.-J.
Kim I.-J.
Chang S.
Koo P.
Kwak J.
Kim J.-H.
10.6084/m9.figshare.5938264.v1
https://karger.figshare.com/articles/dataset/Supplementary_Material_for_Response_of_Retinoic_Acid_in_Patients_with_Radioactive_Iodine-Refractory_Thyroid_Cancer_A_Meta-Analysis/5938264
<p><b><i>Purpose</i></b>: The purpose of this study was to evaluate the
response of retinoic acid (RA) in radioactive iodine (RAI)-refractory
differentiated thyroid cancer (DTC). <b><i>Methods:</i></b> Systematic
searches of MEDLINE (from inception to December 2016) and of EMBASE
(from inception to December 2016) were performed for English-language
publications on thyroid cancer treated with RA. Studies were classified
according to the response criteria used: (1) <sup>123</sup>I or <sup>131</sup>I
whole body scintigraphy (WBS), (2) serum thyroglobulin (Tg) level, (3)
the response evaluation criteria in solid tumors (RECIST) version 1.0,
and (4) World Health Organization (WHO) criteria. <b><i>Results:</i></b>
Disease response rates as determined by WBS ranged widely between 6.2%
and 46.1% with a pooled disease response rate of 27.6% (95% confidence
interval: 21.7-34.0%). Response rates as determined by Tg level ranged
from 56.6% to 83.3% (pooled response rate 61.3% (51.0-70.9%)), RECIST
response rates from 0% to 45.5% (pooled response rate 17.0%
(1.4-44.5%)), and according to WHO criteria, the pooled response rate
was 30.8% (12.7-52.7%). <b><i>Conclusions:</i></b> A minority of patients with RAI-refractory DTC respond to RA treatment.</p>
2018-03-01 10:36:30
Retinoids
Meta-analysis
Thyroid neoplasm
Iodine radioisotopes
Cell differentiation